Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

112.72 -0.27 (-0.24%)
Streaming Delayed Price Updated: 12:01 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
From Gilead Sciences, Inc.
Via Business Wire
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
NAFA Publishes New Fleet Safety Guidebook Aimed at Developing Safety-First Culture in all Organizations
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
Gilead Sciences Announces Second Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
From Gilead Sciences, Inc.
Via Business Wire
NAFA Publishes New Fleet Safety Guidebook Aimed  at Developing Safety-First Culture in all Organizations
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
Via AB Newswire
Topics Death
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program
June 26, 2025 -- Transformative Integrative Breast Cancer Care Program Supports Metastatic Breast Cancer Patients Nationwide 
Via 24-7 Press Release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.